Radiofrequency ablation of high-grade dysplastic nodules

Hepatology

Volumn 54, Issue 6, 2011, Pages 2005-2011

  Cho, Yun Ku ^a   Wook Chung, Jin ^b   Kim, Yoonjung ^a   Je Cho, Hyun ^a   Hyun Yang, Soo ^a  

^a Seoul Veterans Hospital   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CASE REPORT; CONTROLLED STUDY; DISEASE SEVERITY; FOLLOW UP; HIGH GRADE DYSPLASTIC NODULE; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER RESECTION; MALIGNANT TRANSFORMATION; OVERALL SURVIVAL; PRIORITY JOURNAL; PROBABILITY; RADIOFREQUENCY ABLATION; SENSITIVITY ANALYSIS; SURGICAL MORTALITY;

CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; CELL TRANSFORMATION, NEOPLASTIC; COMPUTER SIMULATION; HEPATECTOMY; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MARKOV CHAINS; PRECANCEROUS CONDITIONS; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 82455210770     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.24589     Document Type: Article

References (73)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999; 340: 745-750.
3. Sangiovanni A, Del Ninno E, Fasani P, De Fazio C, Ronchi G, Romeo R, et al. Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology 2004; 126: 1005-1014.
4. Kobayashi M, Ikeda K, Hosaka T, Sezaki H, Someya T, Akuta N, et al. Dysplastic nodules frequently develop into hepatocellular carcinoma in patients with chronic viral hepatitis and cirrhosis. Cancer 2006; 106: 636-647.
5. Takayama T, Makuuchi M, Hirohashi S, Sakamoto M, Okazaki N, Takayasu K, et al. Malignant transformation of adenomatous hyperplasia to hepatocellular carcinoma. Lancet 1990; 336: 1150-1153.
6. Kudo M. Multistep human hepatocarcinogenesis: correlation of imaging with pathology. J Gastroenterol 2009; 44( Suppl 19): 112-118.
7. Trevisani F, Cantarini MC, Wands JR, Bernardi M. Recent advances in the natural history of hepatocellular carcinoma. Carcinogenesis 2008; 29: 1299-1305.
8. Taguchi K, Asayama Y, Aishima S, Nishi H, Sugimachi K, Matsuura S, et al. Morphologic approach to hepatocellular carcinoma development in man: de novo or the so-called 'dysplastic nodule-carcinoma' sequence? Oncol Rep 2002; 9: 737-743.
9. Borzio M, Fargion S, Borzio F, Fracanzani AL, Croce AM, Stroffolini T, et al. Impact of large regenerative, low grade and high grade dysplastic nodules in hepatocellular carcinoma development. J Hepatol 2003; 39: 208-214.
10. Kim SR, Ikawa H, Ando K, Mita K, Fuki S, Sakamoto M, et al. Multistep hepatocarcinogenesis from a dysplastic nodule to well-differentiated hepatocellular carcinoma in a patient with alcohol-related liver cirrhosis. World J Gastroenterol 2007; 13: 1271-1274.
11. Kim SR, Imoto S, Nakajima T, Ando K, Mita K, Taniguchi M, et al. Well-differentiated hepatocellular carcinoma smaller than 15 mm in diameter totally eradicated with percutaneous ethanol injection instead of radiofrequency ablation. Hepatol Int 2009; 3: 411-415.
12. Kojiro M, Roskams T. Early hepatocellular carcinoma and dysplastic nodules. Semin Liver Dis 2005; 25: 133-142.
13. Teo EK, Fock KM. Hepatocellular carcinoma: an Asian perspective. Dig Dis 2001; 19: 263-268.
14. Kim SH, Lim HK, Kim MJ, Choi D, Rhim H, Park CK. Radiofrequency ablation of high-grade dysplastic nodules in chronic liver disease: comparison with well-differentiated hepatocellular carcinoma based on long-term results. Eur Radiol 2008; 18: 814-821.
15. Mulier S, Mulier P, Ni Y, Miao Y, Dupas B, Marchal G, et al. Complications of radiofrequency coagulation of liver tumours. Br J Surg 2002; 89: 1206-1222.
16. Rhim H, Yoon KH, Lee JM, Cho Y, Cho JS, Kim SH, et al. Major complications after radio-frequency thermal ablation of hepatic tumors: spectrum of imaging findings. Radiographics 2003; 23: 123-134; discussion 134-126.
17. Nakanuma Y, Terada T, Ueda K, Terasaki S, Nonomura A, Matsui O. Adenomatous hyperplasia of the liver as a precancerous lesion. Liver 1993; 13: 1-9.
18. Cho YK, Kim JK, Kim MY, Rhim H, Han JK. Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies. HEPATOLOGY 2009; 49: 453-459.
19. Liang P, Dong B, Yu X, Wang Y, Sheng L, Yu D, et al. Sonography-guided percutaneous microwave ablation of high-grade dysplastic nodules in cirrhotic liver. AJR Am J Roentgenol 2005; 184: 1657-1660.
20. Bruix J, Sherman M. Management of hepatocellular carcinoma. HEPATOLOGY 2005; 42: 1208-1236.
21. Takayama T, Makuuchi M, Hirohashi S, Sakamoto M, Yamamoto J, Shimada K, et al. Early hepatocellular carcinoma as an entity with a high rate of surgical cure. HEPATOLOGY 1998; 28: 1241-1246.
22. Nakashima Y, Nakashima O, Tanaka M, Okuda K, Nakashima M, Kojiro M. Portal vein invasion and intrahepatic micrometastasis in small hepatocellular carcinoma by gross type. Hepatol Res 2003; 26: 142-147.
23. Kim BK, Han KH, Park YN, Park MS, Kim KS, Choi JS, et al. Prediction of microvascular invasion before curative resection of hepatocellular carcinoma. J Surg Oncol 2008; 97: 246-252.
24. Okusaka T, Okada S, Ueno H, Ikeda M, Shimada K, Yamamoto J, et al. Satellite lesions in patients with small hepatocellular carcinoma with reference to clinicopathologic features. Cancer 2002; 95: 1931-1937.
25. Bruno S, Zuin M, Crosignani A, Rossi S, Zadra F, Roffi L, et al. Predicting mortality risk in patients with compensated HCV-induced cirrhosis: a long-term prospective study. Am J Gastroenterol 2009; 104: 1147-1158.
26. Naimark DM, Bott M, Krahn M. The half-cycle correction explained: two alternative pedagogical approaches. Med Decis Making 2008; 28: 706-712.
27. Beck JR, Kassirer JP, Pauker SG. A convenient approximation of life expectancy (the "DEALE"). I. Validation of the method. Am J Med 1982; 73: 883-888.
28. Bosman F, Carneiro F, Hruban R, Theise N, Swerdlow S, Campo E, et al. WHO classification of tumours of the digestive system. Lyon, France: International Agency for Research on Cancer, 2010.
29. Di Tommaso L, Franchi G, Park YN, Fiamengo B, Destro A, Morenghi E, et al. Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis. HEPATOLOGY 2007; 45: 725-734.
30. Nascimento C, Caroli-Bottino A, Paschoal J, Pannain VL. Vascular immunohistochemical markers: contributions to hepatocellular nodule diagnosis in explanted livers. Transplant Proc 2009; 41: 4211-4213.
31. Di Tommaso L, Destro A, Seok JY, Balladore E, Terracciano L, Sangiovanni A, et al. The application of markers (HSP70 GPC3 and GS) in liver biopsies is useful for detection of hepatocellular carcinoma. J Hepatol 2009; 50: 746-754.
32. Takayama T, Makuuchi M, Kojiro M, Lauwers GY, Adams RB, Wilson SR, et al. Early hepatocellular carcinoma: pathology, imaging, and therapy. Ann Surg Oncol 2008; 15: 972-978.
33. Frachon S, Gouysse G, Dumortier J, Couvelard A, Nejjari M, Mion F, et al. Endothelial cell marker expression in dysplastic lesions of the liver: an immunohistochemical study. J Hepatol 2001; 34: 850-857.
34. Kojiro M, Wanless IR, Alves V, Badve S, Balabaud C, Bedossa P. Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. HEPATOLOGY 2009; 49: 658-664.
35. Yamauchi N, Watanabe A, Hishinuma M, Ohashi K, Midorikawa Y, Morishita Y, et al. The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma. Mod Pathol 2005; 18: 1591-1598.
36. Llovet JM, Chen Y, Wurmbach E, Roayaie S, Fiel MI, Schwartz M, et al. A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology 2006; 131: 1758-1767.
37. Kudo M. The 2008 Okuda lecture: management of hepatocellular carcinoma: from surveillance to molecular targeted therapy. J Gastroenterol Hepatol 2010; 25: 439-452.
38. Kogita S, Imai Y, Okada M, Kim T, Onishi H, Takamura M, et al. Gd-EOB-DTPA-enhanced magnetic resonance images of hepatocellular carcinoma: correlation with histological grading and portal blood flow. Eur Radiol 2010; 20: 2405-2413.
39. Sun HY, Lee JM, Shin CI, Lee DH, Moon SK, Kim KW, et al. Gadoxetic acid-enhanced magnetic resonance imaging for differentiating small hepatocellular carcinomas (< or =2 cm in diameter) from arterial enhancing pseudolesions: special emphasis on hepatobiliary phase imaging. Invest Radiol 2010; 45: 96-103.
40. Kudo M. Will Gd-EOB-MRI change the diagnostic algorithm in hepatocellular carcinoma? Oncology 2010; 78( Suppl 1): 87-93.
41. Roncalli M, Terracciano L, Di Tommaso L, David E, Colombo M. Liver precancerous lesions and hepatocellular carcinoma: the histology report. Dig Liver Dis; 43 Suppl 4: S361-372.
42. Lencioni R, Caramella D, Bartolozzi C, Di Coscio G. Long-term follow-up study of adenomatous hyperplasia in liver cirrhosis. Ital J Gastroenterol 1994; 26: 163-168.
43. Sakamoto M, Hirohashi S. Natural history and prognosis of adenomatous hyperplasia and early hepatocellular carcinoma: multi-institutional analysis of 53 nodules followed up for more than 6 months and 141 patients with single early hepatocellular carcinoma treated by surgical resection or percutaneous ethanol injection. Jpn J Clin Oncol 1998; 28: 604-608.
44. Livraghi T, Solbiati L, Meloni MF, Gazelle GS, Halpern EF, Goldberg SN. Treatment of focal liver tumors with percutaneous radio-frequency ablation: complications encountered in a multicenter study1. Radiology 2003; 226: 441.
45. Rhim H, Lim HK, Kim YS, Choi D, Lee WJ. Radiofrequency ablation of hepatic tumors: lessons learned from 3000 procedures. J Gastroenterol Hepatol 2008; 23: 1492-1500.
46. Zhou XD, Tang ZY, Yang BH, Lin ZY, Ma ZC, Ye SL, et al. Experience of 1000 patients who underwent hepatectomy for small hepatocellular carcinoma. Cancer 2001; 91: 1479-1486.
47. Ikai I, Arii S, Kojiro M, Ichida T, Makuuchi M, Matsuyama Y, et al. Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey. Cancer 2004; 101: 796-802.
48. Eguchi S, Kanematsu T, Arii S, Okazaki M, Okita K, Omata M, et al. Comparison of the outcomes between an anatomical subsegmentectomy and a non-anatomical minor hepatectomy for single hepatocellular carcinomas based on a Japanese nationwide survey. Surgery 2008; 143: 469-475.
49. Seki S, Sakaguchi H, Kitada T, Tamori A, Takeda T, Kawada N, et al. Outcomes of dysplastic nodules in human cirrhotic liver: a clinicopathological study. Clin Cancer Res 2000; 6: 3469-3473.
50. Lei HJ, Chau GY, Lui WY, Tsay SH, King KL, Loong CC, et al. Prognostic value and clinical relevance of the 6th Edition 2002 American Joint Committee on Cancer staging system in patients with resectable hepatocellular carcinoma. J Am Coll Surg 2006; 203: 426-435.
51. Cho YB, Lee KU, Lee HW, Cho EH, Yang SH, Cho JY, et al. Outcomes of hepatic resection for a single large hepatocellular carcinoma. World J Surg 2007; 31: 795-801.
52. Sumie S, Kuromatsu R, Okuda K, Ando E, Takata A, Fukushima N, et al. Microvascular invasion in patients with hepatocellular carcinoma and its predictable clinicopathological factors. Ann Surg Oncol 2008; 15: 1375-1382.
53. Hui AM, Takayama T, Sano K, Kubota K, Akahane M, Ohtomo K, et al. Predictive value of gross classification of hepatocellular carcinoma on recurrence and survival after hepatectomy. J Hepatol 2000; 33: 975-979.
54. Ueno S, Kubo F, Sakoda M, Hiwatashi K, Tateno T, Mataki Y, et al. Efficacy of anatomic resection vs nonanatomic resection for small nodular hepatocellular carcinoma based on gross classification. J Hepatobiliary Pancreat Surg 2008; 15: 493-500.
55. Roayaie S, Blume IN, Thung SN, Guido M, Fiel MI, Hiotis S, et al. A system of classifying microvascular invasion to predict outcome after resection in patients with hepatocellular carcinoma. Gastroenterology 2009; 137: 850-855.
56. Cho YK, Kim JK, Kim WT, Chung JW. Hepatic resection versus radiofrequency ablation for very early stage hepatocellular carcinoma: a Markov model analysis. HEPATOLOGY; 51: 1284-1290.
57. Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC. Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut 2005; 54: 1151-1156.
58. Minino AM, Heron MP, Murphy SL, Kochanek KD. Deaths: final data for 2004. Natl Vital Stat Rep 2007; 55: 1-119.
59. Tateishi R, Shiina S, Teratani T, Obi S, Sato S, Koike Y, et al. Percutaneous radiofrequency ablation for hepatocellular carcinoma. An analysis of 1000 cases. Cancer 2005; 103: 1201-1209.
60. Livraghi T, Bolondi L, Buscarini L, Cottone M, Mazziotti A, Morabito A, et al. No treatment, resection and ethanol injection in hepatocellular carcinoma: a retrospective analysis of survival in 391 patients with cirrhosis. Italian Cooperative HCC Study Group. J Hepatol 1995; 22: 522-526.
61. Wood TF, Rose DM, Chung M, Allegra DP, Foshag LJ, Bilchik AJ. Radiofrequency ablation of 231 unresectable hepatic tumors: indications, limitations, and complications. Ann Surg Oncol 2000; 7: 593-600.
62. Kaji K, Terada T, Nakanuma Y. Frequent occurrence of hepatocellular carcinoma in cirrhotic livers after surgical resection of atypical adenomatous hyperplasia (borderline hepatocellular lesion): a follow-up study. Am J Gastroenterol 1994; 89: 903-908.
63. Matsui O, Kadoya M, Kameyama T, Yoshikawa J, Arai K, Gabata T, et al. Adenomatous hyperplastic nodules in the cirrhotic liver: differentiation from hepatocellular carcinoma with MR imaging. Radiology 1989; 173: 123-126.
64. Chang S, Kim SH, Lim HK, Lee WJ, Choi D, Lim JH. Needle tract implantation after sonographically guided percutaneous biopsy of hepatocellular carcinoma: evaluation of doubling time, frequency, and features on CT. AJR Am J Roentgenol 2005; 185: 400-405.
65. Chang S, Lim HK. A case of needle tract implantation of hepatocellular carcinoma after percutaneous biopsy with an 18G Tru-cut needle. Korean J Hepatol 2006; 12: 439-443.
66. Riemann B, Menzel J, Schiemann U, Domschke W, Konturek JW. Ultrasound-guided biopsies of abdominal organs with an automatic biopsy system. A retrospective analysis of the quality of biopsies and of hemorrhagic complications. Scand J Gastroenterol 2000; 35: 102-107.
67. Seeff LB, Everson GT, Morgan TR, Curto TM, Lee WM, Ghany MG, et al. Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial. Clin Gastroenterol Hepatol 2010; 8: 877-883.
68. Sakamoto M, Hirohashi S, Shimosato Y. Early stages of multistep hepatocarcinogenesis: adenomatous hyperplasia and early hepatocellular carcinoma. Hum Pathol 1991; 22: 172-178.
69. Takayasu K, Wakao F, Moriyama N, Muramatsu Y, Sakamoto M, Hirohashi S, et al. Response of early-stage hepatocellular carcinoma and borderline lesions to therapeutic arterial embolization. AJR Am J Roentgenol 1993; 160: 301-306.
70. Sharma RR, London MJ, Magenta LL, Posner MC, Roggin KK. Preemptive surgery for premalignant foregut lesions. J Gastrointest Surg 2009; 13: 1874-1887.
71. Nam SW, Park JY, Ramasamy A, Shevade S, Islam A, Long PM, et al. Molecular changes from dysplastic nodule to hepatocellular carcinoma through gene expression profiling. HEPATOLOGY 2005; 42: 809-818.
72. Planas R, Balleste B, Alvarez MA, Rivera M, Montoliu S, Galeras JA, et al. Natural history of decompensated hepatitis C virus-related cirrhosis. A study of 200 patients. J Hepatol 2004; 40: 823-830.
73. Libbrecht L, Desmet V, Roskams T. Preneoplastic lesions in human hepatocarcinogenesis. Liver Int 2005; 25: 16-27.